Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients

Background: Chemotherapy toxicity is a serious problem from which non-small cell lung cancer (NSCLC) patientssuffer. The mismatch repair (MMR) system is associated with platinum-based chemotherapy toxicity in NSCLC patients.In this study, we aimed to investigate the relationship between genetic polymorphisms in the MMR pathway andplatinum-based chemotherapy toxicity in NSCLC patients.Methods: A total of 220 Chinese lung cancer patients who received at least two cycles of platinum-based chemotherapywere recruited for this study. Toxicity was evaluated in each patient after two cycles of chemotherapy. A totalof 44 single nucleotide polymorphisms were selected to investigate their associations with platinum-based chemotherapytoxicity.Results: MutS homolog 2 (MSH2) rs6544991 [odds ratio (OR) 2.98, 95% confidence interval (CI) 1.20–7.40, P = 0.019]was associated with gastrointestinal toxicity in the dominant model; MSH3 rs6151627 (OR 2.38, 95% CI 1.23–4.60,P = 0.010), rs6151670 (OR 2.05, 95% CI 1.07–3.93, P = 0.031), and rs7709909 (OR 2.38, 95% CI 1.23–4.64, P = 0.010)were associated with hematologic toxicity in the dominant model. Additionally, MSH5 rs805304 was significantly associatedwith overall toxicity (OR 2.21, 95% CI 1.19–4.09, P = 0.012), and MSH5 rs707939 was significantly associated withboth overall toxicity (OR 0.42, 95% CI 0.23–0.76, P = 0.004) and gastrointestinal toxicity (OR 0.44, 95% CI 0.20–0.96,P = 0.038) in the dominant model.Conclusion: Genetic polymorphisms in the MMR pathway are potential clinical markers for predicting chemotherapytoxicity in NSCLC patients.